Exact Mass: 690.310556
Exact Mass Matches: 690.310556
Found 99 metabolites which its exact mass value is equals to given mass value 690.310556,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Dalfopristin
C34H50N4O9S (690.3298330000001)
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D025361 - Streptogramins
PGP(i-12:0/i-12:0)
PGP(i-12:0/i-12:0) is a phosphatidylglycerophosphate (PGP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site followed by another phosphate moiety. Phosphatidylglycerolphosphate is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerolphosphate increases during fetal development. Phosphatidylglycerolphosphate may be present in animal tissues merely as a precursor for cardiolipin synthesis. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PGP(i-12:0/i-12:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of isododecanoic acid at the C-2 position. They are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to phosphatidylglycerols (PGs). While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes.
Telmisartan glucuronide
C39H38N4O8 (690.2689508000001)
Zaragozic acid A
10-O-acetylpatrinoside-aglycone-11-O-[4-O-acetyl-alpha-L-rhamnopyranosyl-(1->2)-beta-D-ribohexo-3-ulopyranoside]
20-Deoxy,13-phenylacetyloxy,16-(benzoyloxy),3-benxoyl-Ingenol|20-deoxy-13,16-dihydroxyingenol-3,16-dibenzoate-13-phenylacetate
2,2-bis-(3,4-dimethoxy-phenyl)-5,7,5,7-tetramethoxy-3,4,3,4-tetrahydro-2H,2H-[4,8]bichromenyl-3,3-diol
furost-25(27)-ene-1beta,2beta,3beta,4beta,5beta,6beta,7alpha,22,26-nonaol 26-O-beta-D-glucopyranoside
19-[(1S,4R)-4-hydroxy-1-methoxy-2-oxopentyl]geldanamycin
7-O-acetylpatrinoside-aglycone-11-O-[4-O-acetyl-alpha-L-rhamnopyranosyl-(1->2)-beta-D-ribohexo-3-ulopyranoside]
(1R,2S,4S,5S,6R,7R,8S,9S,10S)-1,2,6,8-tetraacetoxy-9-benzoyloxy-15-(2-methylbutyroyloxy)-4-hydroxydihydro-beta-agarofuran|1alpha,2alpha,6beta,8beta-tetraacetoxy-9alpha-benzoyloxy-15(2)-methylbutyroyloxy-4beta-hydroxy-dihydro-beta-agarofuran
12-acetoxybeyer-15-ene-18-carboxy beta-glucopyranoside pentaacetate
26-O-beta-D-glucopyranosyl furost-5-en-1beta,3beta,22zeta-triol 1-sulphate
C33H54O13S (690.3284954000001)
2,3,5,7,15-pentaacetoxy-8-tigloyloxy-9,14-dioxojatropha-6(17),11E-diene
6-[4-(4-carboxy-3-hydroxy-5-methylphenoxy)carbonyl-3-hydroxy-5-pentadecylphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
His Trp Trp Tyr
His Trp Tyr Trp
His Tyr Trp Trp
Asn Trp Trp Trp
Trp His Trp Tyr
Trp His Tyr Trp
Trp Asn Trp Trp
Trp Trp His Tyr
Trp Trp Asn Trp
Trp Trp Trp Asn
Trp Trp Tyr His
Trp Tyr His Trp
Trp Tyr Trp His
Tyr His Trp Trp
Tyr Trp His Trp
Tyr Trp Trp His
Zaragozic acid A
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents A polyketide isolated from fungi that is a potent inhibitor of fungal and mammalian squalene synthase. D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D009676 - Noxae > D000963 - Antimetabolites D004791 - Enzyme Inhibitors
2,2-BI-9H-FLUORENE, 9,9,9,9-TETRAKIS(4-METHYLPHENYL)-
H-Gly-Arg-Gly-Asp-Ser-Pro-Cys-OH trifluoroacetate salt
C25H42N10O11S (690.2755102000001)
Plazomicin Sulfate
C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic
Bumadizone calcium
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents
DALFOPRISTIN
C34H50N4O9S (690.3298330000001)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D025361 - Streptogramins C254 - Anti-Infective Agent > C258 - Antibiotic
6-[4-(4-Carboxy-3-hydroxy-5-methylphenoxy)carbonyl-3-hydroxy-5-pentadecylphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
1-(4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl)-6-[(E)-4,6-dimethyloct-2-enoyl]oxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
sodium;(2S)-2-[[(2S)-2-[[4-benzyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]oxycarbonylamino]-4-methylpentanoyl]amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate
1-cyclohexyl-3-[(3R,9S,10S)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea
C36H52Cl2N4O5 (690.3314561999999)
N-(2-aminophenyl)-N-[(2R,3R)-2-[[[(4-fluoroanilino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]heptanediamide
1-cyclohexyl-3-[(3S,9S,10S)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea
C36H52Cl2N4O5 (690.3314561999999)
1-cyclohexyl-3-[(3R,9R,10R)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea
C36H52Cl2N4O5 (690.3314561999999)
[1-acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
C33H55O13P (690.3380109999999)
[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
C33H55O13P (690.3380109999999)
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
C33H55O13P (690.3380109999999)
[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
C33H55O13P (690.3380109999999)
[(5R,6E,10R,13R,13aS)-1,2,3a,11,13-pentaacetyloxy-2,5,8,8-tetramethyl-12-methylidene-4,9-dioxo-3,5,10,11,13,13a-hexahydro-1H-cyclopenta[12]annulen-10-yl] (E)-2-methylbut-2-enoate
Z-LEHD-FMK
Z-LEHD-FMK is a selective and irreversible inhibitor of caspase-9, protects against lethal reperfusion injury and attenuates apoptosis. Z-LEHD-FMK exhibits the neuroprotective effect in a rat model of spinal cord trauma[1][2][3].